The first and only fully human agent to selectively target IL-17A, an important mediator in plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis1-4

COSENTYX mechanism of action

  • Selectively binds to IL-17A, inhibiting interaction with IL-17 receptor and subsequent release of proinflammatory cytokines and chemokines1
  • Elevated levels of IL-17A are found in psoriatic plaques and in the blood of patients with psoriatic arthritis1


References: 1. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016. 2. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141-150. 3. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-898. 4. Baeten D. Etiology, pathogenesis, and pathophysiology of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 6th ed. Philadelphia, PA: Elsevier; 2015:102-113.